Mercury poisoning: The Company has Orphan Drug Designation for the Prevention and Treatment of Mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed. Phase 2b is in planning.
COPD: A Phase 2a clinical trial is ongoing for the treatment of COPD and finished by November 2017.
Other conditions: Preclinical studies ongoing for other indications.
Expanded access/Early access: A SwissMedic (Switzerland) and FDA (USA) have approved Irminix® for Named Patient/Compassionate use. For more information – please click above.
Subscribe To Our Mailing List: (* indicates required)